Successful Etanercept Therapy in Therapy-Refractory Acrodermatitis Continua Suppurativa Hallopeau

A 50-year-old patient with acrodermatitis continua suppurativa Hallopeau, characterized by erythema, vesicles, pustules, and interphalangeal joint pain, was unresponsive to various topical treatments and systemic acitretin, which also caused mucosal side effects and hair loss. The introduction of etanercept (2 x 25 mg subcutaneously weekly) led to the resolution of all symptoms within four weeks, including the disappearance of joint pain and improved nail growth. Although symptoms recurred two weeks after discontinuing etanercept, reintroduction of the therapy resulted in rapid clearance. This case suggested that etanercept could be an effective treatment for refractory acrodermatitis continua suppurativa Hallopeau.